Anil Sood

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models
    Chunhua Lu
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 9:176-82. 2010
  2. pmc Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies
    Justin N Bottsford-Miller
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas MD Anderson Cancer Center, Unit 1362, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 30:4026-34. 2012
  3. pmc Markers of angiogenesis in ovarian cancer
    William M Merritt
    Department of Gynecologic Oncology, UT MD Anderson Cancer Center, Unit 1362, PO Box 301439, Houston TX 77230 1439, USA
    Dis Markers 23:419-31. 2007
  4. pmc Src activation by β-adrenoreceptors is a key switch for tumour metastasis
    Guillermo N Armaiz-Pena
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Commun 4:1403. 2013
  5. doi request reprint New directions in reducing stress effects on cancer
    Amal Melhem-Bertrandt
    Department of Breast Medical Oncology, MD Anderson CancerCenter, Houston, USA
    Cancer Prev Res (Phila) 5:147-9. 2012
  6. pmc Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion
    Anil K Sood
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Pathol 165:1087-95. 2004
  7. ncbi request reprint Novel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Obstet Gynecol 105:514-8. 2005
  8. ncbi request reprint Fifth International Conference on Ovarian Cancer: challenges and opportunities
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 97:916-23. 2005
  9. ncbi request reprint Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Expert Opin Pharmacother 6:1269-75. 2005
  10. pmc Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 120:1515-23. 2010

Detail Information

Publications102 found, 100 shown here

  1. pmc Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models
    Chunhua Lu
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 9:176-82. 2010
    ..We tested the efficacy of a highly selective aptamer against PDGF-B with or without anti-VEGF therapy in ovarian cancer models...
  2. pmc Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies
    Justin N Bottsford-Miller
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas MD Anderson Cancer Center, Unit 1362, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 30:4026-34. 2012
    ..Insights gained through this work may offer solutions for personalizing antiangiogenesis approaches and improving the outcome of patients with cancer...
  3. pmc Markers of angiogenesis in ovarian cancer
    William M Merritt
    Department of Gynecologic Oncology, UT MD Anderson Cancer Center, Unit 1362, PO Box 301439, Houston TX 77230 1439, USA
    Dis Markers 23:419-31. 2007
    ..In this article, we review the role of key angiogenesis markers as potential biomarkers in ovarian carcinoma...
  4. pmc Src activation by β-adrenoreceptors is a key switch for tumour metastasis
    Guillermo N Armaiz-Pena
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Commun 4:1403. 2013
    ..Collectively, these data provide a pivotal molecular target for disrupting neural signalling in the tumour microenvironment...
  5. doi request reprint New directions in reducing stress effects on cancer
    Amal Melhem-Bertrandt
    Department of Breast Medical Oncology, MD Anderson CancerCenter, Houston, USA
    Cancer Prev Res (Phila) 5:147-9. 2012
    ....
  6. pmc Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion
    Anil K Sood
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Pathol 165:1087-95. 2004
    ..These data indicate that FAK is overexpressed in most invasive ovarian cancers and plays a functionally significant role in ovarian cancer migration and invasion. Thus, FAK may be an important therapeutic target in ovarian carcinoma...
  7. ncbi request reprint Novel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Obstet Gynecol 105:514-8. 2005
    ..We describe a modification of the traditional vertical rectus abdominis myocutaneous flap for neovagina creation and our experience to date...
  8. ncbi request reprint Fifth International Conference on Ovarian Cancer: challenges and opportunities
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 97:916-23. 2005
    ..This paper provides a summary of the presentations given at the Fifth International Conference on Ovarian Cancer in Houston, Texas on December 1-4, 2004...
  9. ncbi request reprint Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Expert Opin Pharmacother 6:1269-75. 2005
  10. pmc Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 120:1515-23. 2010
    ....
  11. ncbi request reprint Second look laparotomy for ovarian germ cell tumors: to do or not to do?
    A K Sood
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, P O Box 301439, Houston, Texas 77230 1439, USA
    J Postgrad Med 52:246-7. 2006
  12. pmc Stress hormone-mediated invasion of ovarian cancer cells
    Anil K Sood
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230, USA
    Clin Cancer Res 12:369-75. 2006
    ..The purpose of this study is to determine the effects of stress-associated hormones norepinephrine, epinephrine, and cortisol on the invasive potential of ovarian cancer cells...
  13. ncbi request reprint Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6080-5. 2004
    ..The purpose is to investigate the safety and efficacy of i.p. topotecan and oral etoposide as salvage treatment for patients with platinum-resistant ovarian or primary peritoneal cancer...
  14. ncbi request reprint p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 440, Houston, TX 77030 USA
    Cancer Biol Ther 1:511-7. 2002
    ..03). Ovarian cancers with a p53 null mutation are more likely to lack telomerase activity. This may have implications for therapeutic approaches based on telomerase...
  15. ncbi request reprint The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy
    Anil K Sood
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard Unit 440, Houston, Texas 77030, USA
    Cancer Biol Ther 1:661-4. 2002
    ..002) was independently associated with poor survival. This is the first study demonstrating the clinical implications of tumor cell-lined vasculature in ovarian carcinoma...
  16. ncbi request reprint The complexity of tumor vascularity
    Anil K Sood
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 2:257-8. 2003
  17. pmc Stress influences on anoikis
    Anil K Sood
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Cancer Prev Res (Phila) 4:481-5. 2011
    ..This review provides an overview of the relationship between psychosocial factors and the avoidance of anoikis by cancer cells...
  18. ncbi request reprint Highlights from the 2008 Annual Meeting of the American Association for Cancer Research
    Anil K Sood
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 110:5-6. 2008
  19. pmc Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death
    Alpa M Nick
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Natl Cancer Inst 103:1596-612. 2011
    ..We investigated the clinical and biological significance of p130cas, an important cell signaling molecule, in ovarian carcinoma...
  20. ncbi request reprint Functional role of matrix metalloproteinases in ovarian tumor cell plasticity
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Obstet Gynecol 190:899-909. 2004
    ..We also investigated the clinical relevance of matrix metalloproteinase-2 and -9 and membrane type 1-matrix metalloproteinase in human ovarian cancers with evidence of tumor cell-lined vasculature...
  21. pmc Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth
    William M Merritt
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 100:359-72. 2008
    ..Interleukin-8 (IL-8) is a proangiogenic cytokine that is overexpressed in many human cancers. We investigated the clinical and biologic significance of IL-8 in ovarian carcinoma using human samples and orthotopic mouse models...
  22. ncbi request reprint Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors
    Premal H Thaker
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 11:4923-33. 2005
    ....
  23. pmc Therapeutic Targeting of ATP7B in Ovarian Carcinoma
    Lingegowda S Mangala
    Departments of Gynecologic Oncology, Experimental Therapeutics, and Cancer Biology, The University of Texas M D Anderson Cancer Center, USA
    Clin Cancer Res 15:3770-80. 2009
    ..Here, we examined the biological mechanisms and therapeutic potential of targeting a critical platinum resistance gene, ATP7B, using both in vitro and in vivo models...
  24. doi request reprint Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver
    Michael J Gray
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Natl Cancer Inst 100:109-20. 2008
    ..Neuropilin-2 (NRP2) is a high-affinity kinase-deficient receptor for vascular endothelial growth factor (VEGF) and semaphorin 3F. We investigated its function in human colorectal cancers...
  25. pmc Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer
    Tae Jin Kim
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 8:2263-72. 2009
    ..We tested the efficacy of dual targeting of vascular endothelial growth factor (VEGF) and the alpha(V)beta(3) integrin in orthotopic mouse models of ovarian cancer...
  26. pmc Targeted gene silencing using RGD-labeled chitosan nanoparticles
    Hee Dong Han
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Cancer Res 16:3910-22. 2010
    ..This study aimed to develop an Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle (RGD-CH-NP) as a novel tumor targeted delivery system for short interfering RNA (siRNA)...
  27. pmc Dicer, Drosha, and outcomes in patients with ovarian cancer
    William M Merritt
    University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    N Engl J Med 359:2641-50. 2008
    ..We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer...
  28. ncbi request reprint Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer
    Charles N Landen
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 98:1558-70. 2006
    ..We investigated the effects of reduced EphA2 levels on tumor growth and the tumor microenvironment in an orthotopic ovarian cancer model...
  29. ncbi request reprint Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
    William M Merritt
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Cancer Biol Ther 8:1596-603. 2009
    ..Metronomic chemotherapy regimens have shown anti-tumor activity by anti-angiogenic mechanisms, however, the efficacy of metronomic topotecan in ovarian cancer is not known and the focus of the current study...
  30. pmc Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer
    William M Merritt
    Departments of Gynecologic Oncology and Cancer Biology, The University of Texas M D Anderson Cancer Center, Unit 1362, PO Box 301439, Houston, TX 77230 1439, USA
    Mol Cancer Ther 9:985-95. 2010
    ..Mol Cancer Ther; 9(4); 985-95. (c)2010 AACR...
  31. pmc Estrous cycle modulates ovarian carcinoma growth
    Guillermo N Armaiz-Pena
    Department of Gynecologic Oncology and Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 15:2971-8. 2009
    ..The effects of reproductive hormones on ovarian cancer growth are not well understood. Here, we examined the effects of estrous cycle variation and specific reproductive hormones on ovarian cancer growth...
  32. ncbi request reprint Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
    Premal H Thaker
    Department of Gynecologic Oncology, University of Texas U T M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, Texas 77030, USA
    Nat Med 12:939-44. 2006
    ..These data also suggest that blocking ADRB-mediated angiogenesis could have therapeutic implications for the management of ovarian cancer...
  33. ncbi request reprint Genomic instability is associated with lack of telomerase activation in ovarian cancer
    Charles N Landen
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 3:1250-3. 2004
    ..We hypothesized that ovarian cancers with high microsatellite instability (MSI-H) are more likely to lack telomerase activation...
  34. pmc Relaxin/RXFP1 signaling in prostate cancer progression
    Shu Feng
    Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas 77030, USA
    Ann N Y Acad Sci 1160:379-80. 2009
    ..Suppression of RXFP1 expression in PC3 xenografts in nude mice by intratumoral injections of short interfering RNA resulted in decreased tumor size, cell proliferation, and metastasis rate...
  35. pmc EphA2 overexpression promotes ovarian cancer growth
    Chunhua Lu
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 7:1098-103. 2008
    ..We examined the effects of stable EphA2 transfection into poorly invasive ovarian cancer cells with regard to in vitro invasive and in vivo metastatic potential...
  36. pmc Surgical stress promotes tumor growth in ovarian carcinoma
    Jeong Won Lee
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 15:2695-702. 2009
    ..The purpose of this study was to examine the effects of surgical stress on ovarian cancer growth and to determine underlying mechanisms responsible for increased growth...
  37. pmc Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma
    Whitney A Spannuth
    Department of Gynecologic Oncology, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230 1439, USA
    Mol Cancer Ther 9:2377-88. 2010
    ..001), which likely occur through modulation of phosphoinositide 3-kinase signaling. Collectively, these data identify EphB4 as a valuable therapeutic target in ovarian cancer and offer two new strategies for further development...
  38. ncbi request reprint Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
    Aparna A Kamat
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:281-8. 2007
    ..05) and led to a decrease in cell-free DNA levels (P < 0.05). Our results suggest that metronomic taxane chemotherapy with dual EGFR and VEGFR inhibition is highly efficacious and should be considered for future clinical trials...
  39. doi request reprint EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma
    Jeong Won Lee
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:2562-70. 2010
    ..Here, we use an antibody drug conjugate (MEDI-547) composed of a fully human monoclonal antibody against both human and murine EphA2 (1C1) and the tubulin polymerization inhibitor monomethylauristatin F...
  40. ncbi request reprint Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma
    Liz Y Han
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Unit 1362, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 24:755-61. 2006
    ..Tissue factor (TF) is a procoagulant that plays an important part in tumor angiogenesis. We sought to determine the role of preoperative serum TF levels in predicting clinical outcome in patients with ovarian cancer...
  41. pmc Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
    Chunhua Lu
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Obstet Gynecol 198:477.e1-9; discussion 477.e9-10. 2008
    ..The purpose of this study was to examine the functional and therapeutic significance of pericytes in ovarian cancer vasculature...
  42. ncbi request reprint Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma
    Chunhua Lu
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4209-17. 2007
    ..Pericytes are known to provide a survival advantage for endothelial cells. We hypothesize that strategies aimed at dual targeting of tumor-associated endothelial cells and pericytes will be highly efficacious...
  43. pmc EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma
    Jeong Won Lee
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 101:1193-205. 2009
    ....
  44. ncbi request reprint Clinical and biological significance of vascular endothelial growth factor in endometrial cancer
    Aparna A Kamat
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Clin Cancer Res 13:7487-95. 2007
    ..Therefore, we examined the clinical and therapeutic significance of VEGF in endometrial carcinoma using patient samples and an endometrioid orthotopic mouse model...
  45. doi request reprint Angiogenesis as a strategic target for ovarian cancer therapy
    Whitney A Spannuth
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Nat Clin Pract Oncol 5:194-204. 2008
    ..This Review highlights the results of the latest clinical studies of antivascular agents in ovarian cancer and discusses the challenges and opportunities for future clinical trials...
  46. ncbi request reprint Antitumor and antivascular effects of AVE8062 in ovarian carcinoma
    Tae Jin Kim
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:9337-45. 2007
    ..These results suggest that AVE8062 may be useful as a clinical therapeutic approach for ovarian cancer patients and that functional [18F]FDG PET imaging may predict clinical response before an anatomic reduction in tumor size...
  47. ncbi request reprint Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer
    Charles N Landen
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Cancer Res 67:10389-96. 2007
    ....
  48. ncbi request reprint Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism
    Monique B Nilsson
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 282:29919-26. 2007
    ..These results demonstrate that stress hormones activate signaling pathways known to be critical in ovarian tumor progression...
  49. ncbi request reprint Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients
    Charles N Landen
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 13:4098-104. 2007
    ..To assess the clinical significance of Aurora-A kinase, a centrosome-regulating serine-threonine kinase, in ovarian carcinoma...
  50. pmc Novel strategies for reversing platinum resistance
    Mian M K Shahzad
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, USA
    Drug Resist Updat 12:148-52. 2009
    ..The most important targets highlighted here include Aurora kinases, PARP, ATP7B, and ERCC1. Furthermore, we discuss the implications of these novel approaches for ovarian cancer treatment...
  51. pmc Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma
    Hui Guan
    Division of Pediatrics, The University of Texas M D Anderson Cancer Center, Unit 87, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:1807-16. 2008
    ..EWS/FLI-1, which is translocation fusion protein associated with Ewing's sarcoma, regulated Lyn gene expression and kinase activity. These data suggest that targeting Lyn may be a new therapeutic approach in treatment of Ewing's sarcoma...
  52. pmc Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies
    Michael Frumovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 104:768-78. 2007
    ..Nevertheless, VEGF-targeted therapies offer hope for improving the outcome of cancer patients...
  53. pmc Clinical and biological significance of tissue transglutaminase in ovarian carcinoma
    Jee Young Hwang
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:5849-58. 2008
    ..Taken together, these findings indicate that TG2 overexpression is an adverse prognostic factor in ovarian carcinoma and TG2 targeting may be an attractive therapeutic approach...
  54. ncbi request reprint Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway
    Yvonne G Lin
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 13:3423-30. 2007
    ..This study evaluates the effects of curcumin on ovarian cancer growth using an orthotopic murine model of ovarian cancer...
  55. doi request reprint Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma
    Koji Matsuo
    Department of Gynecologic Oncology, M D Anderson Cancer Center, University of Texas, Houston, TX 77230 1439, USA
    Gynecol Oncol 116:61-5. 2010
    ..The objective of this study was to evaluate the clinical significance of the extent of extreme drug resistance (EDR) in in vitro drug resistance assays in advanced epithelial ovarian, fallopian, and primary peritoneal cancers...
  56. pmc Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors
    Longjiang Shao
    Department of Pathology and Immunology and Michael E DeBakey Department of Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 18:6648-57. 2012
    ..Targeting the most common alternatively spliced fusion gene mRNA junctional isoforms in vivo using siRNAs in liposomal nanovectors may potentially be a novel, low-toxicity treatment for prostate cancer...
  57. pmc Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients
    Eileen Huh Shinn
    Department of Behavioral Science, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Palliat Support Care 7:299-306. 2009
    ..Various demographic, medical and psychosocial factors were examined to determine their independent associations with fear of dying and hopelessness in a cross-sectional design...
  58. pmc Regulation of tumor angiogenesis by EZH2
    Chunhua Lu
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 18:185-97. 2010
    ..Collectively, these data support the potential for targeting ezh2 as an important therapeutic approach...
  59. ncbi request reprint Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?
    Jubilee Brown
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler Blvd, Unit 1362, P O Box 301439, TX 77230 1439, USA
    Gynecol Oncol 113:86-90. 2009
    ..Given the paucity of data regarding the patterns of metastasis from ovarian sex cord-stromal tumors (SCSTs), we sought to determine the risk of lymph node metastasis in patients with SCSTs...
  60. ncbi request reprint Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial
    Jubilee Brown
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4973-9. 2010
    ..Because the combination of gemcitabine and cisplatin demonstrated synergism in preclinical studies, the authors attempted to determine the efficacy and toxicity of this combination in women with advanced or recurrent endometrial cancer...
  61. ncbi request reprint Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary
    Kathleen M Schmeler
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Obstet Gynecol 116:269-73. 2010
    ..To estimate the prevalence of lymph node involvement in women with primary mucinous ovarian carcinomas...
  62. doi request reprint Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors
    Xia Tao
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 1439, USA
    Gynecol Oncol 114:431-6. 2009
    ..Ovarian granulosa cell tumors tend to respond poorly to chemotherapy. We examined the clinical efficacy of bevacizumab with or without concurrent chemotherapy and evaluated the angiogenic characteristics of these patients' tumors...
  63. doi request reprint Unmasking the complexities of mucinous ovarian carcinoma
    Michael Frumovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 117:491-6. 2010
    ..The objective of our review was to identify and synthesize the most current information on mucinous ovarian carcinoma with regard to pathologic, molecular, and clinical distinctions...
  64. doi request reprint Pelvic fractures after radiotherapy for cervical cancer: implications for survivors
    Kathleen M Schmeler
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 116:625-30. 2010
    ..The incidence of pelvic fractures and associated risk factors was determined in women treated with curative-intent radiotherapy for cervical cancer...
  65. pmc Functional significance of VEGFR-2 on ovarian cancer cells
    Whitney A Spannuth
    Department of Gynecologic Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 124:1045-53. 2009
    ..001). We show functionally active VEGFR-2 is present on most ovarian cancer cells. The observed anti-tumor activity of VEGF-targeted therapies may be mediated by both anti-angiogenic and direct anti-tumor effects...
  66. pmc Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer
    Charles N Landen
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 10:1259-67. 2008
    ..This study identifies tumor cell alpha(v)beta(3) integrin as an attractive target and defines the Akt pathway as a predictor of response to function-blocking antibody...
  67. ncbi request reprint Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary
    David M Gershenson
    Department of Gynecologic Oncology and Pathology, The University of Texas M D Anderson Cancer Center, Houston, 77230 1439, USA
    Obstet Gynecol 108:361-8. 2006
    ..To analyze the clinical behavior of patients with stage II-IV low-grade serous carcinoma of the ovary seen at our institution who underwent primary surgery followed by platinum-based chemotherapy...
  68. ncbi request reprint The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary
    Rosemarie E Schmandt
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer Biol Ther 5:1136-41. 2006
    ..Its expression in normal ovary and ovarian tumors has not previously been described, and is the focus of this study...
  69. ncbi request reprint Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy
    Robert L Coleman
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 8:455-64. 2006
    ..Further evaluation is warranted to clarify unanswered questions regarding administration schedule, agents, techniques, number of courses, and patient eligibility for intraperitoneal chemotherapy...
  70. doi request reprint Early events in the pathogenesis of epithelial ovarian cancer
    Charles N Landen
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, USA
    J Clin Oncol 26:995-1005. 2008
    ....
  71. ncbi request reprint Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma
    Jyotsnabaran Halder
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:10976-83. 2007
    ..The novel FAK inhibitor, TAE226, offers an attractive therapeutic approach in ovarian carcinoma...
  72. pmc Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy
    Jyotsnabaran Halder
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 12:4916-24. 2006
    ..Based on encouraging in vitro results with FAK silencing, we examined the in vivo therapeutic potential of this approach using short interfering RNA (siRNA) in the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)...
  73. pmc Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
    Xiao Feng Le
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cell Cycle 7:3747-58. 2008
    ..Similar mechanisms may contribute to the clinical anti-tumor activity of trastuzumab in combination with inhibitors of VEGF signaling pathway in women with breast cancers which overexpress HER2...
  74. ncbi request reprint Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer
    Michael Frumovitz
    Department of Gynecologic Oncology, CPB6 3244, Unit 1362, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, TX 77030, USA
    Gynecol Oncol 104:100-3. 2007
    ..To evaluate fundal injection of blue dye and radiocolloid for lymphatic mapping and sentinel node identification in women with high-risk endometrial cancer...
  75. doi request reprint Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
    David M Gershenson
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 114:48-52. 2009
    ..The purpose of this study was to further characterize this chemoresistance in recurrent low-grade serous ovarian carcinoma...
  76. doi request reprint Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma
    Wenhong Ren
    Department of Surgical Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:5466-75. 2008
    ....
  77. ncbi request reprint Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer
    Woojin Jeong
    Department of Systems Biology, The University of Texas M D Anderson Cancer Center, 7435 Fannin Street, Room 2SCR3 2018, Houston, TX 77054, U S A
    Anticancer Res 34:811-7. 2014
    ..We aimed to investigate the clinical significance of the activation of Yes-Associated Protein 1 (YAP1), a key downstream effector of Hippo tumor-suppressor pathway, in ovarian cancer...
  78. ncbi request reprint The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression
    Lin Yang
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:4321-30. 2008
    ..Thus, the hitherto uncharacterized ZKSCAN3 adds to an expanding set of encoded products contributing to the progression of colorectal cancer...
  79. ncbi request reprint Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model
    Limin Hu
    Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143 0556, USA
    Clin Cancer Res 11:6966-71. 2005
    ..9 +/- 38.88 days with no further treatment. We conclude that combination therapy with VEGF Trap plus paclitaxel may provide a novel, long-lasting therapeutic strategy for treatment of patients with ovarian cancer associated with ascites...
  80. ncbi request reprint Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery
    Charles N Landen
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:6910-8. 2005
    ..04 versus 0.22 g; P < 0.001; HeyA8: 0.21 versus 0.84 g; P = 0.0027). These studies show the feasibility of siRNA as a clinically applicable therapeutic modality...
  81. ncbi request reprint Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma
    John P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
    Cancer 98:2199-206. 2003
    ..The purpose of the current study was to determine the relation between MSI of ovarian carcinoma and MMR gene expression, hMLH1 and hMSH2 hypermethylation, and hMLH1 and hMSH2 null mutations...
  82. ncbi request reprint Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines
    Susan K Lutgendorf
    Department of Psychology, University of Iowa, Iowa City, Iowa 52242, USA
    Clin Cancer Res 9:4514-21. 2003
    ..The goal of this study was to examine possible mechanisms underlying these relationships...
  83. ncbi request reprint Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer
    Brian C Cooper
    Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Clin Cancer Res 8:3193-7. 2002
    ..VEGF levels were determined using an ELISA (R&D Systems, Minneapolis, MN)...
  84. ncbi request reprint The paradoxical expression of maspin in ovarian carcinoma
    Anil K Sood
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 1109, USA
    Clin Cancer Res 8:2924-32. 2002
    ..These paradoxical results may offer new insights regarding the role of maspin in ovarian cancer progression that may also impact diagnosis and treatment strategies...
  85. ncbi request reprint Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer
    Brian C Cooper
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City 52242, USA
    Obstet Gynecol 100:59-64. 2002
    ..To estimate the association of preoperative CA 125 levels with outcome in primary ovarian cancer patients...
  86. ncbi request reprint Ovarian cancer p53 mutation is associated with tumor microvessel density
    Michael J Goodheart
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA
    Gynecol Oncol 86:85-90. 2002
    ..The objective of this study was to investigate the relationship between microvessel density, as measured by CD31 staining, and histopathologic factors as well as p53 tumor suppressor gene mutation in ovarian cancer...
  87. ncbi request reprint Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study
    Jeffrey D Bloss
    Division of Gynecologic Oncology, Ellis Fischel Cancer Center, University of Missouri Health Sciences Center, Columbia, USA
    J Clin Oncol 20:1832-7. 2002
    ..This study prospectively evaluates the combination of bleomycin to this regimen in women with histologically proven advanced recurrent or persistent squamous cell carcinoma of the cervix...
  88. ncbi request reprint The embryonic-like properties of aggressive human tumor cells
    Anil K Sood
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242 1109, USA
    J Soc Gynecol Investig 9:2-9. 2002
    ..These results may offer new insights and molecular markers for consideration in ovarian cancer diagnosis and treatment strategies based on molecular vascular mimicry by aggressive tumor cells...
  89. ncbi request reprint Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary
    Tomas Bonome
    Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 65:10602-12. 2005
    ..Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype...
  90. ncbi request reprint EphA2 expression is associated with aggressive features in ovarian carcinoma
    Premal H Thaker
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5145-50. 2004
    ..EphA2 (epithelial cell kinase) is a transmembrane receptor tyrosine kinase that has been implicated in oncogenesis. There are no published data regarding the role of EphA2 in ovarian carcinoma, which is the focus of the present study...
  91. ncbi request reprint Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma
    Chunhua Lu
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:1757-68. 2007
    ..The present study shows that tumor and normal endothelium differ at the molecular level, which may have significant implications for the development of antiangiogenic therapies...
  92. ncbi request reprint Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells
    Eric V Yang
    Department of Molecular Virology, The Ohio State University Medical Center, Columbus, OH 43210, USA
    Cancer Res 66:10357-64. 2006
    ..The data suggest that catecholamine hormones produced by the sympathetic-adrenal medullary axis may affect NPC tumor progression, in part, through modulation of key angiogenic cytokines...
  93. ncbi request reprint Analysis of EphA2 expression and mutant p53 in ovarian carcinoma
    William M Merritt
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer Biol Ther 5:1357-60. 2006
    ..Taken together, these data indicate a complex relationship between EphA2 and p53 that appears to regulate EphA2 expression and clinical outcome...
  94. ncbi request reprint Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma
    Aparna A Kamat
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer Biol Ther 5:1369-74. 2006
    ..We sought to determine whether tumor-specific plasma DNA could be used as a biomarker for tumor burden and response to therapy in an orthotopic ovarian cancer model...
  95. pmc Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma
    Liz Y Han
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 66:8633-9. 2006
    ..Thus, Src inhibition may be an attractive therapeutic approach for patients with ovarian carcinoma...
  96. ncbi request reprint Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer
    Charles N Landen
    Department of Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 5:1708-13. 2006
    ..We sought to determine whether intraperitoneal (IP) delivery of these siRNA complexes was as effective at delivery and therapy as IV delivery...
  97. pmc Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients
    Susan K Lutgendorf
    Department of Psychology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 26:4820-7. 2008
    ..The objective of the current study was to examine associations between IL-6, diurnal cortisol rhythms, and facets of depression in epithelial ovarian cancer patients...
  98. pmc Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells
    Jyotsnabaran Halder
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8829-36. 2005
    ..Docetaxel causes cell death through induction of apoptosis; however, cell death characteristics for docetaxel have not yet been fully elucidated. We examined the role of focal adhesion kinase (FAK) cleavage in docetaxel-mediated apoptosis...
  99. ncbi request reprint The role of relaxin in endometrial cancer
    Aparna A Kamat
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 5:71-7. 2006
    ..In turn, downregulation of endogenous RLN signaling decreases invasiveness of endometrial cancer cells. These novel findings may have therapeutic implications in the management of patients with endometrial carcinoma...
  100. ncbi request reprint EphA2 as a target for ovarian cancer therapy
    Charles N Landen
    Department of Gynecologic Oncology, U T M D Anderson Cancer Center, Houston, TX 77030, USA
    Expert Opin Ther Targets 9:1179-87. 2005
    ....

Research Grants13

  1. Tumor metastasis: Biobehavioral mechanisms
    Anil Sood; Fiscal Year: 2007
    ..abstract_text> ..
  2. Ovarian Cancer: Mechanisms of Neuroendocrine Regulation
    Anil K Sood; Fiscal Year: 2010
    ..The results from this work could be important for designing new methods of treatment of cancer patients. ..
  3. Tumor metastasis: Biobehavioral mechanisms
    Anil Sood; Fiscal Year: 2005
    ..abstract_text> ..
  4. Ovarian Cancer: Mechanisms of Neuroendocrine Regulation
    Anil Sood; Fiscal Year: 2009
    ..The results from this work could be important for designing new methods of treatment of cancer patients. ..
  5. Tumor metastasis: Biobehavioral mechanisms
    Anil Sood; Fiscal Year: 2006
    ..abstract_text> ..
  6. Tumor metastasis: Biobehavioral mechanisms
    Anil Sood; Fiscal Year: 2004
    ..abstract_text> ..
  7. Ovarian Cancer: Mechanisms of Neuroendocrine Regulation
    Anil Sood; Fiscal Year: 2007
    ..Findings of this study could lead to identification of novel mechanisms underlying accelerated ovarian cancer growth and therefore may lead to new therapeutic approaches. ..
  8. Tumor metastasis: Biobehavioral mechanisms
    Anil Sood; Fiscal Year: 2006
    ..abstract_text> ..
  9. Ovarian Cancer: Mechanisms of Neuroendocrine Regulation
    Anil Sood; Fiscal Year: 2006
    ..Findings of this study could lead to identification of novel mechanisms underlying accelerated ovarian cancer growth and therefore may lead to new therapeutic approaches. ..
  10. Ovarian Cancer: Mechanisms of Neuroendocrine Regulation
    Anil Sood; Fiscal Year: 2005
    ..Findings of this study could lead to identification of novel mechanisms underlying accelerated ovarian cancer growth and therefore may lead to new therapeutic approaches. ..
  11. Tumor metastasis: Biobehavioral mechanisms
    Anil K Sood; Fiscal Year: 2009
    ....